[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lung-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lung-diseases":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,44,0,25,[9,48,74,108,134,160,191,221,248,283,315,336,360,384,410,431,454,480,498,526,546,576,597,622,650],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100510155","phase-2-belumosudil-for-bronchiolitis-obliterans-preventiontherapy-bebop-100510155",false,"NCT05922761","BElumosudil for Bronchiolitis Obliterans Prevention\u002FTherapy (BEBOP)","An Open-Label, Phase 2 Study to Evaluate the Activity of Belumosudil in Subjects With New Onset and Incipient Bronchiolitis Obliterans Syndrome Following Allogeneic Hematopoietic Cell Transplantation","Inclusion Criteria Cohort A:\n\n* Diagnosis of BOS after HCT using pulmonary function testing, per the NIH diagnostic criteria17 OR the Atypical BOS criteria33 3.1.2.1 NIH Diagnostic Criteria for BOS. All of the following must be met:\n\n  * FEV1\u002FVC \\\u003C 0.7 or \\\u003C5th percentile of predicted (FEV1 = Forced Expiratory Volume in 1 second; VC = Vital Capacity (either FVC, Forced Vital Capacity, or SVC, Slow Vital Capacity, whichever is greater)\n  * FEV1 \\\u003C75% of predicted with ≥ 10% absolute decline over less than 2 years. FEV1 should not correct to \\>75% of predicted with albuterol, and the absolute decline for the corrected values should still remain ≥ 10% over 2 years.\n  * Absence of active infection in the respiratory tract, documented with investigations directed by clinical symptoms, such as chest radiographs or computed tomographic scans or microbiologic cultures (sinus aspiration, upper respiratory tract viral screen, sputum culture, bronchoalveolar lavage).\n  * One of the two supporting features of BOS:\n\n    * i - Evidence of air trapping by expiratory CT or small airway thickening or bronchiectasis by high-resolution chest CT OR\n    * ii - Evidence of air trapping by PFTs: RV (Residual Volume) \\> 120% of predicted or RV\u002FTLC elevated outside the 90% confidence interval (RV\u002FTotal Lung Capacity).\n* Atypical Criteria for BOS:\n\n  * FEV1 \\\u003C80% of predicted with ≥ 10% absolute decline over the last 2 years or since transplant. The remote comparator can be an evaluation of PFTs done within 2 years of the PFTs assessment being evaluated to determine eligibility or the PFT assessment done prior to transplant.\n  * VC \\\u003C 80% of predicted.\n  * FEV1\u002FVC \\> 0.7.\n  * Absence of active infection in the respiratory tract, documented with investigations directed by clinical symptoms, such as chest radiographs or computed tomographic scans or microbiologic cultures (sinus aspiration, upper respiratory tract viral screen, sputum culture, bronchoalveolar lavage) or active non-infectious lung disease (such as interstitial lung disease) that explain spirometric changes or chest CT findings.\n\nInclusion Criteria for Cohort B:\n\n-Diagnosis of BOS-0p\n\n* Decline in FEV1 of 10% - 19% of predicted compared with pretransplant testing OR\n* Decline in predicted FEF25-75% (Forced Expiratory Flow between 25% and 75% of vital capacity) \\> 25%\n\nInclusion Criteria for Cohorts A and B:\n\n* Age ≥18 years. Belumosudil is currently being tested in pediatric populations and the safety and efficacy in pediatric patients have not yet been established. A protocol amendment to include pediatric patients will be considered once safety in pediatric patients is established.\n* ECOG performance status ≤2 (Karnofsky ≥ 60%).\n* Participants must have adequate organ and marrow function as defined below:\n\n  * WBC ≥ 3,000\u002FμL\n  * Absolute neutrophil count ≥ 1,500\u002F μL\n  * Platelets ≥ 50,000\u002FmcL\n  * AST(SGOT)\u002FALT(SGPT) ≤ 5 × institutional ULN\n* No evidence of relapsed malignancy at the time of enrollment. Formal re-staging is not required for trial entry.\n* All females of childbearing potential must have a negative serum or urine pregnancy test \\\u003C 7 days before study drug administration.\n* The ability to understand and willingness to sign a written consent document.\n\nExclusion Criteria for Cohorts A and B:\n\n* Participants who have received prior therapy specifically for BOS. Therapy for cGVHD in the absence of BOS is permissible.\n* Prior exposure to belumosudil.\n* Participants who are receiving any other investigational immunosuppressive agents for cGVHD.\n* Presence of an active uncontrolled infection. An active uncontrolled infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs, or radiographic findings attributable to infection. Persistent fever without signs or symptoms will not be interpreted as an active uncontrolled infection.\n* Known human immunodeficiency virus infection. Interactions between belumosudil and anti-retroviral agents have not been established.\n* Active hepatitis B virus (HBV) or hepatitis C virus infection that requires treatment or at risk for HBV reactivation. At risk for HBV reactivation is defined as hepatitis B surface antigen positive or anti-hepatitis B core antibody positive. Subjects with previous positive serology results must have negative polymerase chain reaction results. Subjects whose immune status is unknown or uncertain must have results confirming immune status before enrollment.","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this research study is to test the efficacy of a novel immunosuppressive agent, belumosudil, in allogeneic hematopoietic stem cell transplant (HSCT) recipients who have been newly diagnosed or have developing (early stage) bronchiolitis obliterans syndrome (BOS).\n\nThe name of the study drugs involved in this study are:\n\n* Belumosudil (an immunotherapy)\n* Fluticasone (an intranasal corticosteroid)\n* Azithromycin (an antibiotic)\n* Montelukast (a leukotriene receptor antagonist)\n* Prednisone (a corticosteroid)",[27,28,29,30],"Bronchiolitis Obliterans Syndrome","Bronchiolitis Obliterans","Lung Diseases","Chronic Graft Versus Host Disease",[27,28,32,33,34,30],"Lung Disease","Allogeneic hematopoietic stem cell transplant","HSCT","RECRUITING","2026-06-08",{"date":38,"type":39},"2026-06-10","ACTUAL",{"date":41,"type":39},"2024-05-31",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"Dana-Farber Cancer Institute","OTHER",6,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100610422","data-collection-using-eko-digital-devices-in-a-clinical-setting-100610422","NCT07227376","Data Collection Using Eko Digital Devices in a Clinical Setting","Inclusion Criteria:\n\n* Suspected or diagnosed lower respiratory condition OR Presence of wheeze, coarse crackle, fine crackle, rhonchus, stridor, rales, and cough discovered during routine auscultation\n* Normal patients with no adventitious lung sounds\n* Adults and pediatric patients (as available)\n\nExclusion Criteria:\n\n* Unable to have multiple recordings taken on chest and back (e.g. compromised mobility)\n* On mechanical ventilation",{"count":55,"type":21},250,"OBSERVATIONAL","The purpose of this research is to prospectively train and validate an artificial intelligence machine learning (ML) algorithm to detect the presence of adventitious lung sounds in adults. Clinicians will use the Eko CORE and\u002For Eko CORE 500 device(s) in real clinical settings to collect normal and abnormal lung sounds, as part of standard of care clinical practice, which will then be used to explore an ML algorithm for classifiers for wheeze, coarse crackle, fine crackle, rhonchus, stridor, rales, and cough, as well as determine any correspondences between the type and\u002For location of adventitious lung sounds and the type of pulmonary conditions as reported by clinicians.",[29],[60,61,62],"lung sounds","adventitious lung sounds","abnormal lung sounds","2026-05-21",{"date":65,"type":39},"2026-05-26",{"date":67,"type":39},"2025-09-14",{"date":69,"type":21},"2027-11-30",{"name":71,"class":72},"Eko Devices, Inc.","INDUSTRY",2,{"id":75,"slug":76,"hasResults":12,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":86,"conditions":87,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100382700","phase-4-clinical-surveillance-vs-anticoagulation-for-low-risk-patients-with-isolated-subsegmental-pulmonary-embolism-100382700","NCT04263038","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism","Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism: a Multicenter Randomized Placebo-controlled Non-inferiority Trial","SAFE-SSPE","Inclusion Criteria:\n\n1. Informed Consent as documented by signature\n2. Age ≥18 years\n3. Objective diagnosis of symptomatic or asymptomatic isolated SSPE\n\nExclusion Criteria:\n\n1. Presence of leg deep vein thrombosis (DVT) or upper extremity DVT (subclavian vein or above)\n2. Active cancer, defined as cancer treated with surgery, chemotherapy, radiotherapy, or palliative care during the last 6 months\n3. ≥1 prior episode of unprovoked VTE (absence of a transient or permanent risk factor)\n4. Clinical instability (systolic blood pressure \\\u003C100 mm Hg or arterial Oxygen saturation \\\u003C92% at ambient air) at the time of presentation\n5. Active bleeding or at high risk of bleeding\n6. Severe renal failure (creatinine clearance \\\u003C30ml\u002Fmin)\n7. Severe liver insufficiency (Child-Pugh B or C)\n8. Concomitant use of strong CYP3A4 inhibitors or strong CYP3A4 inducers\n9. Known hypersensitivity to rivaroxaban\n10. Need for therapeutic anticoagulation for another reason\n11. Therapeutic anticoagulation for \\>72 hours for any reason at the time of screening\n12. Hospitalized for \\>72 hours prior to the diagnosis of isolated SSP (hospital-acquired VTE)\n13. Known pregnancy or breast feeding (pregnancy test to be performed for women of childbearing potential)\n14. Lack of safe contraception in women of childbearing potential\n15. Refusal or inability to provide informed consent\n16. Prior enrolment in this trial",{"count":83,"type":21},276,[85],"PHASE4","The clinical significance of pulmonary embolism (PE) limited to the subsegmental pulmonary arteries, so called isolated subsegmental pulmonary embolism (SSPE), remains controversial. Whether isolated SSPE represents \"true\" PE, a clinically more benign form of PE, a physiologic lung clearing process, or a false positive result (artifact) is currently unclear and hence, whether patients with isolated SSPE benefit from anticoagulant treatment is uncertain. Despite growing evidence from observational studies that withholding anticoagulation may be a safe option in selected patients with isolated SSPE (i.e., those without concomitant deep vein thrombosis, cancer, etc.), most patients with isolated SSPE receive anticoagulant treatment, which is associated with an increased risk of bleeding. The overall objective of the randomized controlled SAFE-SSPE trial is to evaluate the efficacy and safety of clinical surveillance without anticoagulation compared to anticoagulation treatment in low-risk patients with isolated SSPE.",[88,89,90,29,91,92,93,94,95],"Pulmonary Embolism","Embolism","Embolism and Thrombosis","Cardiovascular Diseases","Respiratory Tract Diseases","Venous Thromboembolism","Anticoagulant-induced Bleeding","Bleeding",[97],"subsegmental pulmonary embolism","2026-05-20",{"date":100,"type":39},"2026-05-22",{"date":102,"type":39},"2020-05-15",{"date":104,"type":21},"2028-05",{"name":106,"class":46},"Drahomir Aujesky",40,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":133},"100549255","phase-3-study-of-treatment-with-sacituzumab-and-zimberelimab-for-patients-with-lung-cancer-confined-to-the-chest-and-previously-operated-on-who-were-not-disease-free-100549255","NCT06431633","Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.","A Phase III Clinical Trial of Adjuvant Treatment With Sacituzumab and Zimberelimab for Stage IB-IIIA-IIIB(N2) Previously Resected (R0) Non-small Cell Lung Cancer Patients That Did Not Achieve Pathological Complete Response After Neoadjuvant treatment_ARIAN","ARIAN","Inclusion Criteria:\n\n* 1\\. Patients diagnosed of primary non-small cell lung cancer, histologically confirmed.\n* 2\\. Patients should be classified postoperatively in stage IB, IIA, IIB, IIIA or IIIB (N2) according to pathological criteria (pTNM) and according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology\n* 3\\. Complete surgical resection (R0) of the primary NSCLC is also essential. Surgeons are strongly advised to dissect or obtain samples of all accessible lymph node levels, as established in the European Society of Thoracic Surgeons guide. Consequently, at the end of the surgical intervention it is recommended to have obtained samples of a minimum of 3 specific mediastinal ganglionic lobe stations (N2), one of which should include station 7, and at least one N1 station\n* 4\\. The surgical intervention may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy, as determined by the responsible surgeon based on intraoperative findings. Patients who have had only segmentectomies or wedge resections are not considered eligible for participation in this study except if R0 resection can be confirmed.\n* 5\\. Only patients that do not achieve pathological complete response (pCR) seen in the surgical piece after neoadjuvant therapy are eligible.\n* 6\\. Preoperative (neoadjuvant) use of platinum-based chemotherapy + immunotherapy (anti PD-1) is mandatory.\n* 7\\. Preoperative, postoperative, or scheduled radiation therapy is not accepted for a later time. Patients with only N2 disease, who have to receive post-operative adjuvant radiotherapy will not be eligible.\n* 8\\. A minimum of 3 weeks must have elapsed between the surgical intervention performed for the NSCLC and the randomization. Adjuvant treatment must start between the 3rd and the 10th week from surgery.\n* 9\\. Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* 10\\. Patients aged ≥ 18 years.\n* 11\\. PDL1 value analysed locally (hospital must be able to provide this value before randomization)\n* 12\\. PET-CT and brain CT before randomization to confirm the absence of distant disease.\n* 13\\. Adequate hematologic and organ function\n* 14.All patients are notified of the investigational nature of this study and signed a written in-formed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention.\n* 15.For female patients of childbearing potential, agreement (by patient and\u002For partner) to use a highly effective form(s) of contraception\n* 16\\. For male patients with female partners of childbearing potential, agreement (by patient and\u002For partner) to use a highly effective form(s) of contraception\n* 17\\. Oral contraception should always be combined with an additional contraceptive method because of a potential interaction with the study drugs.\n* 18.Women who are not postmenopausal or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug.\n* 19.Patient capable of proper therapeutic compliance and accessible for correct follow-up\n* 20\\. Patients with a life expectancy of at least more than 12 weeks\n\nExclusion Criteria:\n\n* 1\\. Patients with a history of other malignant diseases, with the exception of the following:\n\n  * properly treated non-melanotic skin cancer\n  * cancer in situ treated with curative intent or other malignancies treated with curative intent and without signs of disease for a period of\\> 3 years after the end of the treatment and which, in the opinion of the doctor in charge of their treatment, do not present a substantial risk of relapse of the previous malignant disease.\n* 2.T4 patients with invasion of heart, great vessels, carina, trachea, oesophagus or spine\n* 3\\. Patients with ALK translocation, STK11 o KEAP1 known mutations before inclusion in this trial.\n* 4\\. Patients with adenocarcinoma NSCLC must be tested for the common EGFR mutations before inclusion. Patients with any known EGFR mutation cannot be enrolled in the study.\n* 5\\. Patients with a combination of microcytic and non-small cell lung cancer, a carcinoid lung tumor or large cell neuroendocrine carcinoma\n* 6\\. Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of randomization.\n* 7\\. Patients that received live attenuated vaccines within 30 days prior to randomization\n* 8\\. History of a primary immunodeficiency, history of organ allogeneic transplantation, use of immunosuppressive drugs within 28 days before randomization or previous history of toxicity of severe immune mechanism (grade 3 or 4) with other immunological treatments\n* 9\\. Patients with active or uncontrolled infections or with serious medical conditions or disorders that may not allow patient management as established in the protocol.\n* 10\\. Patients who have suffered untreated and \u002F or uncontrolled cardiovascular disorders and \u002F or who have symptomatic cardiac dysfunction\n* 11\\. Pregnant or breastfeeding women\n* 12\\. Patients in whom R0 resection cannot be confirmed.\n* 13\\. Patients with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.\n* 14.Patients with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization. Inhaled or topical steroids, and adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.\n* 15\\. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV). In patients with a history of HBV or HCV, patients with detectable viral loads will be excluded.\n* 16\\. History of allergy or hypersensitivity to any of the study drug components\n* 17\\. Pleural or pericardial effusion, both will be considered indicative of metastatic disease unless proven otherwise. Patients with pleural effusion not visible on chest-X-ray or too small to perform diagnostic puncture safely may be included.\n* 18\\. Have known history of HIV-1 or 2 with detectable viral load OR taking medications that may interfere with SN-38 metabolism.\n* 19.Severe infections within 4 weeks prior to be included in the study, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.\n* 20.Patients with medical, mental, neurological or psychological condition which in the opinion of the investigator would not permit the patient to understand the patient information sheet or comply with study procedures.\n* 21\\. Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder; any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement; or prior pneumonectomy.\n* 22\\. Treatment with systemic immunosuppressive medications\n* 23.Patients with uncontrolled comorbidities that may affect the clinical trial compliance.\n* 24.Sexually active men and women of childbearing potential who are not willing to use an effective contraceptive method during the study.",{"count":117,"type":21},129,[119],"PHASE3","Open-label, phase III, randomized, stratified (PDL1- vs PDL1+), 3 arms, multicenter clinical trial.\n\n129 resected patients (43 per arm) with stage from IB to IIIA and IIIB (N2) non-small cell lung cancer that do not achieve pathologic complete response (pCR) after neoadjuvant treatment.\n\nThis clinical trial has 3 arms of treatment. ARM 1: Observation 10 months, ARM 2: treatment with immunotherapy (Zimberelimab) for 13 cycles and ARM 3: treatment with Sacituzumab Govitecan and Zimberelimab for 8 cycles and Zimberelimab monotherapy for 5 cycles.\n\nThe primary objective is to evaluate the disease-free survival (DFS): defined as the length of time from randomization to the earliest event defined as disease recurrence, any new lung cancer (even in the opposite lung), or death from any cause at any known point in time.\n\nPatient accrual is expected to be completed within 2 years, treatment is planned to extend during 1 years and the patients will be followed up for 2 years. The study will end once survival follow-up has concluded.",[29,122,123],"Carcinoma, Non-Small-Cell Lung","Resectable Lung Non-Small Cell Carcinoma","2026-05-14",{"date":126,"type":39},"2026-05-18",{"date":128,"type":39},"2025-02-04",{"date":130,"type":21},"2031-11-30",{"name":132,"class":46},"Fundación GECP",32,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":12,"sex":17,"minAge":141,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100460700","trikafta-exercise-study-in-cystic-fibrosis-100460700","NCT05279040","Trikafta Exercise Study in Cystic Fibrosis","Long-term Effects of Elexacaftor\u002FTezacaftor\u002FIvacaftor (Trikafta) on Exertional Symptoms, Exercise Performance, Ventilatory Responses, and Body Composition in Adults With Cystic Fibrosis","Inclusion Criteria:\n\n* Confirmed diagnosis of CF and at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene\n* Plan to initiate Trikafta by the treating physician within 30 days of the enrolment visit\n* Aged 19 years or older\n* Stable clinical status based on clinical judgment of the treating physician\n* Forced Expiratory Volume in 1 second (FEV1.0) \\\u003C 90% predicted\n* Body mass index greater than 16 or less than 30 kg\u002Fm\\^2\n* Currently non-smoking or a past smoking history of less than 20 pack-years\n* Able to read and understand English\n* Fully vaccinated (at least 2 doses) for Covid-19\n\nExclusion Criteria:\n\n* A disease other than CF that could importantly contribute to dyspnea or exercise limitation\n* Chronic airway infection with Mycobacterium abscessus, Burkholderia cepacia complex, or other organisms with infection control implications based on the treating physicians\n* Contraindications to clinical exercise testing\n* Use of supplemental oxygen or desaturation less than 85% with exercise\n* Diagnosis of pneumothorax in the past 4 weeks\n* History of organ transplantation","19 Years",{"count":143,"type":21},20,"Shortness of breath (dyspnea) during exercise is a major source of distress and is a commonly reported symptom in patients with cystic fibrosis (CF). A recent drug treatment option known as Trikafta, which contains elexacaftor, tezacaftor, and ivacaftor, may be used in patients with CF to help improve lung health. However, the effects of this combination therapy on dyspnea and exercise performance, a known predictor of survival in CF, are not clear. The investigators aim to understand the effects of Trikafta on these symptoms and to gain new insight into the potential health improvements in CF from using this treatment option.",[146,29],"Cystic Fibrosis",[148,149,150],"Dyspnea","Exercise","Trikafta","2026-05-13",{"date":126,"type":39},{"date":154,"type":39},"2021-11-10",{"date":156,"type":21},"2027-01",{"name":158,"class":46},"University of British Columbia",1,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":168,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":173,"conditions":174,"keywords":178,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":189,"locationsCount":4},"100636612","revised-paravertebral-nerve-blocks-for-enhanced-recovery-after-video-assisted-thoracoscopic-pneumonectomy-100636612","NCT07567950","Revised-Paravertebral Nerve Blocks for Enhanced Recovery After Video-assisted Thoracoscopic Pneumonectomy","Revised-Paravertebral Nerve Blocks for Video-Assisted Thoracoscopic Surgery: A Randomized, Controlled, Observer-masked Noninferiority Trial.","r-PVB-1","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for elective video-assisted thoracoscopic pneumonectomy for benign or malignant diseases\n\nExclusion Criteria:\n\n* Contraindications to nerve block, including skin infection at the puncture site, increased intracranial pressure, uncorrectable coagulopathy, bridging indication for therapeutic anticoagulation (CHADS-VASc ≥ 8), sepsis, or allergy to local anesthetics\n* Surgeon-estimated high likelihood of conversion to open surgery\n* Chronic opioid use\n* Heart failure, liver failure, or renal failure\n* Coagulation disorders\n* History of allergy to local anesthetics\n* Inability to comply with the study protocol, including severe psychiatric illness, refusal to provide informed consent, or anticipated difficulty with postoperative follow-up",true,{"count":170,"type":21},200,[172],"NA","Revised-Paravertebral Nerve Block (r-PVB) is performed right after induction of general anesthesia and before lateral positioning of surgery. Under ultrasound guidance, an intercostal space between the 6th and 8th ribs at the midaxillary line is identified. Using an in-plane technique, the needle is advanced into the internal intercostal muscle, and 30 mL of 0.5% ropivacaine is injected to achieve the block. Traditional Paravertebral Nerve Block (PVB) is performed right after the lateral positioning of surgery under ultrasound guidance. According to the operator's preference, choose any of the commonly used three traditional paravertebral block approaches. Among these 3 approaches, the axial plane approach is recommended as the first choice: use the convex probe to identify the 6th and 8th transverse processes, then scan cranially to display the superior costotransverse ligament, pleura, and paravertebral space. Under sterile conditions, insert the needle in-plane approximately 2 cm lateral to the probe, ensuring the ultrasound probe remains stable and dynamically visualizing the needle advancement. Stop advancing the needle when the tip passes through the superior costotransverse ligament. Administer 2% lidocaine in pulsatile injections, 1-2 ml per pulse, observing the spread of fluid at the needle tip on ultrasound and depression of the pleura. Repeat pulsatile injections until a total of 5 ml lidocaine is administered, and if necessary, increase with another 5 ml of pulsatile lidocaine. The fluid movement and pleura depression observed on ultrasound confirm proper needle placement. Then, use this needle to inject 30 ml of 0.5% ropivacaine to complete the PVB. The surgical procedure will start right after the intervention blocks.",[175,176,177,29],"Video-assisted Thoracoscopic Surgery (VATS)","Postoperative Pain","Quality of Recovery",[179,176,177,180,181],"Video-Assisted Thoracoscopic Surgery","Paravertebral Nerve Block","intercostal space block","NOT_YET_RECRUITING","2026-05-05",{"date":185,"type":39},"2026-05-08",{"date":187,"type":21},"2026-05-06",{"date":43,"type":21},{"name":190,"class":46},"Sixth Affiliated Hospital, Sun Yat-sen University",{"id":192,"slug":193,"hasResults":12,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":4,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":22,"phases":200,"briefSummary":201,"conditions":202,"keywords":207,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":159},"100618558","phase-2-a-study-of-mosliciguat-in-combination-with-inhaled-treprostinil-in-ph-ild-100618558","NCT07333183","A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD","An Open-Label, Phase 2 Study Evaluating the Safety of Mosliciguat in Combination With Inhaled Treprostinil in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease","Inclusion Criteria:\n\n* Participants willing and able to provide informed consent\n* Participants on inhaled treprostinil\n* Participants with diagnosis of Interstitial Lung Disease (ILD). Diagnosis will be confirmed by a high-resolution computerized tomography (HR-CT) scan showing diffuse parenchymal disease. Eligible diagnosed diseases include:\n\n  1. Idiopathic interstitial pneumonia (IIP)\n  2. Chronic hypersensitivity pneumonitis\n  3. ILD associated with connective tissue disease (CTD) with a forced vital capacity (FVC) \\\u003C 70% of predicted\n* Confirmed pulmonary hypertension (PH) by right heart catheterization (RHC).\n* Ability to perform 6MWD ≥100 meters.\n\nExclusion Criteria:\n\n* Diagnosis of PH Group 1 (eg. pulmonary arterial hypertension), Group 2 (related to left-heart dysfunction), Group 4 (eg, chronic thromboembolic pulmonary hypertension), or Group 5 (eg, unclassified).\n* Exacerbation of underlying lung disease within 28 days prior to randomization.\n* Initiation of pulmonary rehabilitation within 28 days prior to randomization.\n* Receiving \\>10 L\u002Fmin of oxygen supplementation by any mode of delivery at rest at Baseline.\n* History or intolerance to or lack of efficacy with mosliciguat or sGC stimulators or activators.\n* Receipt of investigational, or experimental therapy within 42 days OR 5 half-lives prior to randomization.\n\nNote: Other inclusion and exclusion criteria may apply.","85 Years",{"count":143,"type":21},[24],"This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD) on a background inhaled treprostinil.",[203,204,29,205,91,206],"Pulmonary Hypertension","Interstitial Lung Disease (ILD)","Vascular Diseases","Fibrosis",[208,209,210,211],"PH","ILD","6 Minute Walk Test","mosliciguat","2026-04-18",{"date":214,"type":39},"2026-04-22",{"date":216,"type":39},"2025-12-23",{"date":218,"type":21},"2028-01",{"name":220,"class":72},"Pulmovant, Inc.",{"id":222,"slug":223,"hasResults":12,"nctId":224,"briefTitle":225,"officialTitle":226,"acronym":227,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":229,"minAge":4,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":232,"conditions":233,"keywords":237,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":159},"100572087","lung-ultrasound-in-critically-ill-obstetrics-and-gynecological-patients-100572087","NCT06728709","Lung Ultrasound in Critically Ill Obstetrics and Gynecological Patients","Perioperative Lung Ultrasound Phenotypes and Clinical Outcomes in Critically Ill Obstetrics and Gynaecologic Patients (POLUS): A Prospective Cohort Study","POLUS","Inclusion Criteria:\n\n* Any patient admitted to the obstetrics and gynecology intensive care unit\n\nExclusion Criteria:\n\n* Patient's refusal\n* inability to do a lung ultrasound examination during the first 24 hours of admission","FEMALE",{"count":231,"type":21},64,"Pulmonary dysfunction aggravates the illness of critically ill obstetrics and gynecological patients. Early identification with bedside technique and prompt management may improve the outcome of critical care in this vulnerable population",[234,235,29,236],"Obstetric Complication","Gynecologic Cancer","Ultrasound",[238,239,240],"lung ultrasound","critically ill peripartum","critically ill gynecological cases",{"date":214,"type":39},{"date":243,"type":39},"2024-12-15",{"date":245,"type":21},"2026-05-01",{"name":247,"class":46},"Ain Shams University",{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":17,"minAge":255,"maxAge":256,"enrollmentInfo":257,"targetDuration":4,"studyType":22,"phases":259,"briefSummary":260,"conditions":261,"keywords":268,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":281,"locationsCount":159},"100443196","respiratory-muscles-and-work-of-breathing-in-children-100443196","NCT05051254","Respiratory Muscles and Work of Breathing in Children","WOB&MR_Ped","Inclusion Criteria:\n\n* Patients aged less than 18 years old with primary or secondary impairment of respiratory muscles and followed at Necker Hospital\n* Patients under spontaneous breathing or noninvasive or invasive mechanical ventilation\n* Written informed consent\n\nExclusion Criteria:\n\n* No social insurance\n* Significant psychomotor retardation\n* Absence of cooperation\n* Significant agitation\n* Hemodynamic instability\n* Acute condition or temporary drug treatments that may interfere with the results of the respiratory muscle explorations","0 Years","17 Years",{"count":258,"type":21},550,[172],"Respiratory muscle testing allows a quantitative assessment of inspiratory and expiratory muscles in children of any age with primary or secondary respiratory muscle impairment, in order to better understand the pathophysiology of respiratory impairment and guide therapeutic management. The use of an invasive technique (esogastric probe) makes it possible to specifically explore the diaphragm, the accessory inspiratory muscles and the expiratory muscles in order to detect dysfunction or paralysis of these muscles, and to estimate the work of breathing in order to better guide the respiratory management.\n\nThe primary objective of the study is to evaluate the respiratory effort in children with primary or secondary impairment of the respiratory muscles during spontaneous breathing or during mechanical ventilation.",[262,263,29,264,265,266,267],"Neuromuscular Diseases","Congenital Diaphragmatic Hernia","Cardiac Diseases","Scoliosis","Diaphragmatic Impairment","Respiratory Muscle Impairment",[269,270,271,272,273,274],"Respiratory muscle testing","Respiratory muscle strength","Work of breathing","Esogastric pressures","Diaphragmatic dysfunction","Diaphragmatic paralysis","2026-03-30",{"date":277,"type":39},"2026-04-03",{"date":279,"type":39},"2022-01-19",{"date":218,"type":21},{"name":282,"class":46},"Assistance Publique - Hôpitaux de Paris",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":289,"eligibilityCriteria":290,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":291,"targetDuration":4,"studyType":22,"phases":293,"briefSummary":294,"conditions":295,"keywords":296,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":159},"100479617","comparison-of-two-strategies-of-one-lung-ventilation-in-patients-undergoing-carcinological-lung-resection-surgery-100479617","NCT05525312","Comparison of Two Strategies of One-lung Ventilation in Patients Undergoing Carcinological Lung Resection Surgery.","Comparison of Two Strategies of One-lung Ventilation in Patients Undergoing Carcinological Lung Resection Surgery: \"Open Lung\" Approach With Individualized Level of Positive End-expiratory Pressure Titrated According to the Best Lung Compliance, Versus \"Standard\" Care: a Randomized Controlled Trial","I-PEEP-THO","Inclusion Criteria:\n\n* To be over 18 years old,\n* To be able to attend all scheduled visits and to comply with all trial procedures,\n* To be scheduled for a lung cancer resection surgery (performed by either video-assisted thoracoscopy or thoracotomy).\n\nExclusion Criteria:\n\n* Non-carcinologic indication of lung resection (e.g. Lung volume reduction for bullous emphysema reduction, lung abscess),\n* Bilateral pulmonary resection surgery or history of lung resection surgery,\n* Lung resection under sternotomy\n* Non intubated video-assisted thoracoscopy\n* Robotic thoracic surgery\n* Contraindication to esophageal catheter (history of esophageal varices, hepatic cirrhosis child ≥ b, esophageal or gastric surgery, thoracic radiotherapy, latex allergy),\n* ASA (American Society of Anesthesiologists) score ≥ 4,\n* Chronic obstructive pulmonary disease GOLD III or IV (Forced Expiratory Volume, FEV\\\u003C50%),\n* Uncontrolled asthma (FEV \\\u003C50%),\n* Intracardiac shunt,\n* Hemoglobinopathy making the SpO2 values invalid,\n* Heart failure NYHA III or IV,\n* Documented pulmonary hypertension (Mean Pulmonary Arterial Pressure at rest, mPAP\\>20 mmHg),\n* To be under legal protection,\n* Unable to read or write,\n* Lack of informed consent, or unable to give consent,\n* Refusal to participate in the study,\n* Pregnancy in progress or planned during the study period, pregnant or nursing women,\n* Not being affiliated to a French social security system or being a beneficiary of such a system.",{"count":292,"type":21},120,[172],"During thoracic surgery, one-lung ventilation (OLV) is associated with hypoxemia, lung injury, and perioperative respiratory complications. The level of positive-end expiratory pressure (PEEP) to apply during OLV remains controversial. The open-lung approach consists in setting a level of PEEP corresponding to the best lung compliance, using an esophageal catheter to measure the transpulmonary pressure. This approach has been effective in laparoscopic surgeries or acute respiratory distress syndrome, but has never been evaluated in thoracic surgery.",[29],[297,298,299,300,301,302,303,304,305],"Pulmonary resection surgery","One lung ventilation","Positive end-expiratory pressure","Esophageal pressure","Transpulmonary pressure","Lung compliance","Protective ventilation","Hypoxemia","Postoperative complications","2026-03-25",{"date":308,"type":39},"2026-03-31",{"date":310,"type":39},"2024-03-20",{"date":312,"type":21},"2027-06-20",{"name":314,"class":46},"University Hospital, Montpellier",{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":327,"lastUpdatePostDateStruct":328,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":159},"100554049","prophylaxis-guided-by-cytomegalovirus-specific-t-cell-immunity-to-prevent-cytomegalovirus-disease-in-lung-transplant-recipients-100554049","NCT06494033","Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients","Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients: a Single Center Prospective Study","Inclusion Criteria:\n\n1. Adult patients over 18 years of age\n2. Lung transplant candidates with positive CMV IgG\n3. Anticipated to receive a lung transplant (both double lung and single lung)\n\nExclusion Criteria:\n\n1. Negative CMV IgG prior transplant\n2. Pregnant or breastfeeding women\n3. HIV infected patients\n4. Combined organ (e.g., lung-heart, lung-kidney) transplant candidates","75 Years",{"count":324,"type":21},100,"The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.",[29],"2026-03-18",{"date":329,"type":39},"2026-03-23",{"date":331,"type":39},"2024-07-03",{"date":333,"type":21},"2026-12-30",{"name":335,"class":46},"University of Miami",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":341,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":344,"briefSummary":345,"conditions":346,"keywords":347,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":159},"100512165","defining-a-technique-for-the-use-of-cryogenic-catheters-for-biopsy-and-ablation-for-the-diagnostic-and-treatment-of-pulmonary-lesions-an-ex-vivo-human-lung-model-study-100512165","NCT05948904","Defining a Technique for the Use of Cryogenic Catheters for Biopsy and Ablation for the Diagnostic and Treatment of Pulmonary Lesions: An Ex-Vivo Human Lung Model Study.","CT0129","Inclusion Criteria:\n\n* Patients undergoing lung transplant surgery\n\nExclusion Criteria:\n\n* Organ donor ineligible to donate lungs\n* Healthy individuals",{"count":170,"type":21},[172],"Developing a standardized methodology for the use of novel cryogenic catheters for transbronchial cryobiopsy and cryoablation of pulmonary lesions.",[29],[348,349,350,351],"Lung","cryobiopsy","cryoablation","transbronchial intervention","2026-03-17",{"date":327,"type":39},{"date":355,"type":39},"2023-11-03",{"date":357,"type":21},"2027-04-01",{"name":359,"class":46},"Centre hospitalier de l'Université de Montréal (CHUM)",{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":366,"eligibilityCriteria":367,"healthyVolunteers":168,"sex":17,"minAge":368,"maxAge":369,"enrollmentInfo":370,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":383},"100529741","deep-functional-phenotyping-of-the-ala-lung-health-cohort-100529741","NCT06177717","Deep Functional Phenotyping of the ALA Lung Health Cohort","The American Lung Association (ALA) Deep Phenotyping Ancillary Study of the Lung Health Cohort (LHC)","DLP-LHC","Inclusion Criteria:\n\n* Age 25-35 years at the time of the baseline examination\n* Able to read and understand English or Spanish\n* Has a social security number\n* Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination.\n\nNote: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.\n\n* Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant\n\nExclusion Criteria:\n\n1. Severe asthma, which is defined as any of the following:\n\n   * Current (i.e. at the time of the visit) Global Initiative for Asthma (GINA) Step 4 or higher therapy (medium dose inhaled corticosteroid\u002Flong-acting beta agonist (ICS\u002FLABA) or high dose inhaled corticosteroid \\[ICS\\] or add-on long-acting muscarinic antagonist (LAMA); Medium dose = \\>250 fluticasone, propionate =100 fluticasone furoate, \\>200 beclomethasone, \\>400 budesonide, \\>220 mometasone). The investigators will accept low-dose ICS\u002FLABA or medium dose ICS.\n\n   OR\n   * 3 or more unscheduled healthcare visits (provider\u002Furgent care\u002FER) for asthma in the past 12 months OR\n   * One asthma hospitalization in the past 12 months\n2. History of any chronic lung disease other than asthma including but not limited to chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary fibrosis, pulmonary hypertension\n3. Current pregnancy\n4. History of cancer other than non-melanoma skin cancer\n5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)\n6. Inability to comply with study procedures, including\n\n   * Inability or unwillingness to provide informed consent\n   * Inability to perform study measurements\n   * Inability to be contacted by phone (via calls and\u002For text messaging) or email\n7. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).\n8. Institutionalization","25 Years","35 Years",{"count":371,"type":21},1000,"The goal of this observational study is to learn about lung structure and function in a group of 1000 healthy people aged 25 to 35. The main questions it aims to answer are whether people's bodies, environment, and general lung health are associated with:\n\n* the structure of the participants lungs' airways,\n* the structure of blood vessels in the participants lungs and heart, and\n* the participants lungs' ability to exchange gases.\n\nParticipants will take four different lung function tests to measure lung function, including:\n\n* air movement in the lungs (oscillometry)\n* lung size (slow vital capacity (SVC) and functional residual capacity (FRC)\n* gas transfer in the lungs (diffusing capacity for carbon monoxide (DLCO).",[29],"2026-03-04",{"date":376,"type":39},"2026-03-06",{"date":378,"type":39},"2024-02-12",{"date":380,"type":21},"2026-07-30",{"name":382,"class":46},"Johns Hopkins University",12,{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":168,"sex":17,"minAge":368,"maxAge":369,"enrollmentInfo":391,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":393,"conditions":394,"keywords":395,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":409},"100404217","american-lung-association-ala-lung-health-cohort-100404217","NCT04543461","American Lung Association (ALA) Lung Health Cohort","The American Lung Association (ALA) Lung Health Cohort","Inclusion Criteria:\n\n1- Age 25-35 years at the time of the baseline examination 2- Able to read and understand English or Spanish 3 -Has a social security number 4- Resident (citizen or non-citizen) of the United States (US) for at least 12 months prior to examination. Note: Individuals who are residents of the US who have temporarily spent time living outside of the US during the last 12 months (e.g., student exchange program, military posting) are eligible for participation.\n\n5- Willing to provide contact information for at least 2 proxies who are likely to know the whereabouts and vital status of the participant\n\nExclusion Criteria:\n\n1. Severe asthma, which is defined as any of the following:\n\n   1. Current (i.e. at the time of the visit) GINA Step 4 or higher therapy (medium dose ICS\u002FLABA or high dose ICS or add-on LAMA; Medium dose = \\>250 fluticasone, propionate =100 fluticasone furoate, \\>200 beclomethasone, \\>400 budesonide, \\>220 mometasone). We will accept low-dose ICS\u002FLABA or medium dose ICS.\n\n      OR\n   2. 3 or more unscheduled healthcare visits (provider\u002Furgent care\u002FER) for asthma in the past 12 months OR\n   3. One asthma hospitalization in the past 12 months\n2. History of any chronic lung disease other than asthma including but not limited to COPD, cystic fibrosis, pulmonary fibrosis, pulmonary hypertension\n3. Current pregnancy\n4. History of cancer other than non-melanoma skin cancer\n5. Diagnosed cardiovascular diseases (i.e., congenital heart disease, coronary heart disease)\n6. Inability to comply with study procedures, including\n\n   1. Inability or unwillingness to provide informed consent\n   2. Inability to perform study measurements\n   3. Inability to be contacted by phone (via calls and\u002For text messaging) or email\n7. Any condition in the opinion of the physician that puts the participant at risk by participating in the study (e.g., serious respiratory illness requiring antibiotics or steroids or severe fever at the time of the study visit).\n8. Institutionalization",{"count":392,"type":21},4000,"The ALA-LHC is a longitudinal, multi-center cohort study that will enroll approximately 4,000 young adults between the ages of 25-35 who do not have severe lung disease. The overarching objective of the ALA-LHC is to establish a national cohort of young adults for the purpose of defining lung health and developing targets to intercept chronic lung disease at its earliest stages.",[29],[396,397,398,399,400],"lung health","environmental exposure","chest CT","spirometry","biomarkers","2026-02-02",{"date":403,"type":39},"2026-02-04",{"date":405,"type":39},"2021-10-29",{"date":407,"type":21},"2026-09",{"name":382,"class":46},37,{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":417,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":159},"100413484","bio-banking-of-specimens-for-advanced-lung-disease-and-lung-transplant-research-100413484","NCT04664192","Bio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research","ALD Biobank","Inclusion Criteria:\n\n1. All individuals aged 18 years and older\n2. Persons who have undergone lung transplantation at Baylor University Medical Center in the previous 10 years\n3. Individual is able to understand and sign the informed consent form\n\nExclusion Criteria:\n\n1. Significant documented anemia (hemoglobin \\\u003C8 g\u002FdL)\n2. Blood transfusions within past 3 weeks\n3. Active cancer (non-skin cancers)\n4. Enrollment against doctor recommendation\n5. Patient not able to provide informed consent",{"count":324,"type":21},"A major goal of this protocol is to support biomarker studies in advanced lung diseases, lung transplantation care, and to improve our understanding of the effects of viral and other infectious exposures to outcomes in our lung transplant and ALD patient populations.",[420,421,29],"Respiratory Failure","Interstitial Lung Disease","2026-01-28",{"date":424,"type":39},"2026-01-30",{"date":426,"type":39},"2021-06-04",{"date":428,"type":21},"2026-12-01",{"name":430,"class":46},"Baylor Research Institute",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":4,"eligibilityCriteria":436,"healthyVolunteers":168,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":437,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":439,"conditions":440,"keywords":441,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":445,"lastUpdatePostDateStruct":446,"startDateStruct":448,"completionDateStruct":450,"leadSponsor":452,"locationsCount":159},"100620319","the-use-of-electrical-impedance-tomography-eit-in-pulmonary-diseases-100620319","NCT07356076","The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Individuals diagnosed with any of the following lung diseases, as these are the primary focus of the study: Chronic obstructive pulmonary disease, Asthma, Pulmonary fibrosis, Pneumonia, Patients with a history of COVID-19 infection showing residual pulmonary findings.\n* Additionally, healthy subjects will be enrolled to obtain normal standard values (with normal physical examination and no respiratory symptoms, BMI 18-36 - cause EIT performance can be BMI dependent, Non-smokers or ex-smokers abstinent ≥12 months)\n* Ability to perform spirometry while seated, except for possible participants who are specifically part of a subgroup analysis where inability to perform spirometry is the condition which is studied.\n\nSigning of an informed consent that has been approved by the ethics committee\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Severe cardiovascular disease\n* Pregnancy\n* Inability to express consent\n* Acute respiratory infection: Except for those recovering from pneumonia or COVID-19 within the study focus, participants with current respiratory infections will be excluded to avoid confounding effects on lung function tests\n* Inability to perform spirometry",{"count":438,"type":21},400,"The study titled \"The Use of Electrical Impedance Tomography (EIT) in Pulmonary Diseases\" investigates the impact of using EIT as a non-invasive method to monitor the distribution of pulmonary ventilation and its relationship to standard spirometry in patients with various lung diseases. The main aim of this study is to investigate new approaches to the assessment of lung status and diagnosis of lung diseases.\n\nUnlike spirometry, which has long been a well-known and important diagnostic tool in pulmonary medicine, and which provides valuable information about the volume and flow of inspired and expired air, EIT provides spatial information about the distribution of ventilation in real time and without the need for active patient cooperation. Research and practice have shown that spirometry is problematic in specific groups of patients, such as patients with tracheostomy or facial palsy. The technology should also enable detection of the disease in its early stages, when treatment is most effective.\n\n300 participants in the experimental group and 100 participants in the control group will receive spirometry and electrical impedance tomography independent examination.\n\nThe primary endpoint of the study is to investigate the potential of EIT in respiratory medicine, specifically identifying the relationship between EIT and traditional spirometry. This effort is motivated by the need for novel noninvasive methods for the diagnosis and monitoring of respiratory diseases, especially in patients unable to undergo conventional spirometry, or in case of interventions requiring real-time feedback. The purpose of the research project in relation to these objectives is to bring new possibilities in the field of diagnosis and monitoring of lung diseases through EIT, which could lead to significant improvements in patient care.\n\nDemographic and anthropometric data, including age, sex, body height, body weight, body mass index (BMI), chest circumference, and smoking history will be collected in all participants. These parameters will be used as covariates in the analysis to assess their impact on EIT-derived indicators and to improve normalization of EIT signals.\n\nAdditionally, the study aims to develop and validate a machine learning model, particularly a deep neural network, capable of predicting standard spirometric parameters (e.g., FEV1, FVC, PEF) based solely on EIT signals. This could allow for an accurate assessment of dynamic pulmonary volumes in cooperating patients who are unable to undergo conventional spirometry (e.g. patients with tracheostomy).",[29],[442,443,29,444],"Electrical Impedance Tomography","Spirometry","Lung Assessment","2026-01-25",{"date":447,"type":39},"2026-01-27",{"date":449,"type":39},"2025-11-01",{"date":451,"type":21},"2028-12-31",{"name":453,"class":46},"University Hospital Olomouc",{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":460,"eligibilityCriteria":461,"healthyVolunteers":12,"sex":17,"minAge":462,"maxAge":4,"enrollmentInfo":463,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":465,"conditions":466,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":159},"100504917","cough-capture-as-a-portal-into-the-lung-100504917","NCT05854563","Cough Capture as a Portal Into the Lung","Genetics of Lung Disease (Exhaled Breath DNA Methylation in Lung Carcinogenesis)","CC1","Inclusion Criteria:\n\n* Age: minimum age of 21 years\n* Gender: Male and Female adults\n* Ethnicity: All ethnic groups and races\n* Subjects undergoing bronchoscopy for diagnostic purposes or therapy\n* Subjects without a known diagnosis of lung cancer who are not scheduled for lung tissue collection procedures\n* Subjects with a known or suspected diagnosis of asthma or COPD and are scheduled for a visit at Montefiore Asthma or COPD Center and individual practices, and\u002For in-hospital with exacerbation\n\nExclusion Criteria:\n\n* Bleeding diathesis or known coagulopathy precluding clinically indicated biopsy (e.g., INR\\>1.3, PTTr\\>1.3), thrombocytopenia \\\u003C50,000, uremia with serum creatinine \\>3.0\n* Unstable angina\n* Recent myocardial infarction (within 3 months),\n* Uncontrolled congestive heart failure or severe pulmonary hypertension (mean PAP\\>75 mmHg)","21 Years",{"count":464,"type":21},2000,"The lung is a privileged organ; blood does not reflect most lung processes well, if at all. Therefore, for population scale diagnostics, the investigator team is developing non-invasive portals to the lung, for eventual early detection\u002Frisk assessment and diagnostic purposes. However, large macromolecules are not likely suspended nor readily detected in the breath. In particular, genomic DNA in the breath condensate (EBC) is very sparse, and where present, generally highly fragmented, not readily amenable to sequencing based assessments of DNA somatic mutation burden or distribution. Because gDNA (and protein) is challenging to obtain non-invasively from EBC, the study team considered alternative surrogate lower airway specimens. Cough capture is rarely done, and the investigator team is in the process of optimizing its collection. Importantly, the team will be evaluating how much of coughed material is from saliva contamination. Additionally, analyzing material that is target captured by capturing deep lung extracellular vesicles (EVs) using immobilized CCSP\u002FSFTPC antibodies targeting EVs from distal bronchiole Club and alveolar type 2 cells could circumvent the mouth contamination problem, leaving a non-invasive portal to the deep lung suitable for large molecules, and in turn suitable for myriad epidemiologic and clinical applications.\n\nThe investigator team proposes (Aim 1) to pursue optimizing cough collection, and testing the efficacy and practicality of partitioning cough specimen for deep-lung specific extra-cellular vesicles (EVs). This cough specimen will be compared to that from invasively collected deep lung samples BAL\u002Fbronchial brushings, and to the potential contaminating mouth rinse, all from the same individuals. (Aim 2) The study team initially proposes to examine these cough specimens for somatic mutations by SMM bulk sequencing for single nucleotide variation, developed in the Vijg\u002FMaslov labs. Finally, the investigator team will (Aim 3) test all airway specimens (cough, mouthwash and BAL) for lung surrogacy of cough, using proteins known to be specific for lung, as opposed to oral cavity\u002Fsaliva, in the Sidoli\u002Fproteomics core.\n\nThe investigator team envisions that the translational impact of non-invasively obtained DNA or protein markers could allow for more rapid acute clinical diagnoses, and facilitate precision prevention and\u002For early detection of many acute and chronic respiratory disorders, including lung cancer, asthma and COPD, acute and chronic infectious diseases, and indeed systemic disorders of inflammation and metabolism.",[29,467,468,469,470],"Lung Cancer","Lung Diseases, Obstructive","Lung Diseases, Interstitial","Lung Inflammation","2026-01-12",{"date":473,"type":39},"2026-01-13",{"date":475,"type":39},"2023-03-28",{"date":477,"type":21},"2027-06",{"name":479,"class":46},"Albert Einstein College of Medicine",{"id":481,"slug":482,"hasResults":12,"nctId":483,"briefTitle":484,"officialTitle":52,"acronym":4,"eligibilityCriteria":485,"healthyVolunteers":168,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":487,"conditions":488,"keywords":489,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":159},"100613757","data-collection-using-eko-devices-in-a-clinical-setting-100613757","NCT07270744","Data Collection Using Eko Devices in a Clinical Setting","Inclusion Criteria:\n\n* Patients suspected or diagnosed lower respiratory condition OR Presence of wheeze, coarse crackle, fine crackle, rhonchus, stridor, rales, and cough discovered during routine auscultation\n* Normal patients with no adventitious lung sounds\n* Adults patients, over 18 years old\n* Able to provide verbal consent\n\nExclusion Criteria:\n\n* Patients unable to have multiple recordings taken on chest and back (e.g. compromised mobility)\n* Patients on mechanical ventilation\n* Patients unwilling or unable to provide informed consent",{"count":170,"type":21},"The main objectives of the study are to: train and validate binary classifiers for wheeze, coarse crackle, fine crackle, rhonchus, stridor, rales, and cough, as well as determine correspondence between type\u002Flocation of adventitious lung sound and type of pulmonary condition.",[29],[60,61,62],"2025-12-10",{"date":492,"type":39},"2025-12-18",{"date":494,"type":39},"2025-10-01",{"date":496,"type":21},"2026-12-31",{"name":71,"class":72},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":4,"eligibilityCriteria":504,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":322,"enrollmentInfo":505,"targetDuration":4,"studyType":22,"phases":507,"briefSummary":508,"conditions":509,"keywords":513,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":518,"lastUpdatePostDateStruct":519,"startDateStruct":521,"completionDateStruct":523,"leadSponsor":524,"locationsCount":159},"100574393","phase-2-post-line-treatment-with-teniposide-for-c-myc-driven-extensive-stage-small-cell-lung-cancer-100574393","NCT06758700","Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer","Phase II Clinical Study to Evaluate the Efficacy and Safety of Teniposide as a Post-Line Therapy for c-Myc-Driven Extensive-Stage Small Cell Lung Cancer","Inclusion Criteria:\n\n1. extensive stage small cell lung cancer\n2. Progression after receiving at least one chemotherapy drug treatment in the past;\n3. ECOG score 0-1\n4. c-Myc-driven\n5. Expected survival period ≥3 months\n6. Age: 18-75 years old;\n7. The informed consent form complies with the ICH-GCP principles.\n\nExclusion Criteria:\n\n1. No measurable lesions\n2. Other severe and persistent diseases or organ system dysfunction;\n3. Women planning pregnancy or men planning family planning;\n4. Women who are pregnant or breastfeeding;\n5. Those who cannot follow the research protocol provided by the investigator.",{"count":506,"type":21},15,[24],"The study is being conducted to investigate the efficacy and safety of teniposide in patients with extensive-stage small cell lung cancer who have failed standard treatment and with high expression of the c-Myc-driven FBXW2\u002FMYC gene. Based on the results, the study will explore the correlation between the expression of FBXW2\u002FMYC and the efficacy of teniposide.",[510,511,512,29],"Extensive-stage Small Cell Lung Cancer (ES-SCLC)","Thoracic Neoplasms","Lung Neoplasms",[514,515,516,517],"c-Myc","SCLC","Phase II","Post-line","2025-11-30",{"date":520,"type":39},"2025-12-05",{"date":522,"type":39},"2025-02-07",{"date":496,"type":21},{"name":525,"class":46},"Shanghai Pulmonary Hospital, Shanghai, China",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":533,"targetDuration":535,"studyType":56,"phases":4,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":542,"leadSponsor":544,"locationsCount":159},"100611698","multi-omics-based-prediction-of-allograft-dysfunction-after-lung-transplantation-100611698","NCT07243964","Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation","Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation: A Prospective, Multicenter Cohort Study","Inclusion Criteria:\n\n1. Recipients aged ≥18 years undergoing single or double lung transplantation;\n2. Postoperative recipients capable of understanding and providing written informed consent, and willing to comply with scheduled follow-ups and sample collections as required by the study;\n3. Postoperative recipients clinically assessed as stable and eligible for routine follow-up and hematological examinations;\n4. Recipients able to undergo dynamic pulmonary function monitoring during follow-up;\n5. No planned participation in other interventional trials during the study period that may impact immune function or pulmonary function;\n6. Retransplant patients will be considered as a new transplant event and may be included in the analysis.\n\nExclusion Criteria:\n\n1. History of active malignancy or presence of untreated malignancy within 5 years prior to transplantation;\n2. Presence of active systemic infection or significant immune rejection;\n3. Female patients who are pregnant or lactating;\n4. Any other condition deemed by the investigator to be inappropriate for inclusion .",{"count":534,"type":21},244,"2 Years","By establishing a prospective, multicenter lung transplantation clinical cohort, this study aims to systematically evaluate the utility of cfDNA fragmentomics, peripheral blood single-cell sequencing, and proteomics in monitoring and predicting graft dysfunction after lung transplantation, and to develop a multi-omics predictive model for early identification, dynamic monitoring, and mechanistic investigation of acute lung allograft dysfunction (ALAD) and chronic lung allograft dysfunction (CLAD).",[29],"2025-11-21",{"date":540,"type":39},"2025-11-24",{"date":449,"type":39},{"date":543,"type":21},"2030-03-01",{"name":545,"class":46},"Chang Chen",{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":551,"acronym":552,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":22,"phases":556,"briefSummary":557,"conditions":558,"keywords":563,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":569,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":143},"100586607","phase-2-palace-cemiplimab-trial-according-to-ctdna-levels-100586607","NCT06917573","PALACE: Cemiplimab Trial According to ctDNA Levels","Phase II Clinical Trial With an Adaptive Design According to Response to Cemiplimab Monotherapy Using ctDNA and Subsequent Treatment With Chemotherapy (CT) and Cemiplimab or Cemiplimab Monotherapy in First Line Advanced NSCLC Patients","PALACE","Inclusion Criteria:\n\n* Histologically confirmed stage IV or stage IIIB\u002FC not candidates for definitive chemo\u002Fradiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy\n* PDL1 ≥50%\n* ECOG performance status 0-1\n* Patients aged ≥ 18 years\n* Prior adjuvant or neoadjuvant chemotherapy for early stage is permitted if completed at least 6 months prior to enrolment\n* Presence of at least one measurable lesion by CT-scan per RECIST version 1.1\n* Anticipated life expectancy \\>12 weeks\n* Correct hematological, hepatic and renal function\n* Patient consent must be obtained in the appropriate manner as established in the applicable local and regulatory requirements\n* Patients must be accessible for treatment and follow-up\n* Women of childbearing potential, including women who had their last menstrual period in the last 2 years, must have a negative serum or urine pregnancy test within 3 days before enrolment.\n* All sexually active men and women of childbearing potential must use a highly effective contraceptive method during the study treatment and for a period of at least 4 months following the last administration of trial drugs\n\nExclusion Criteria:\n\n* Patients whose tumors harbor an activating mutation in EGFR, ALK translocation, or ROS Proto-Oncogene 1 (ROS1) rearrangements sensitive to available targeted inhibitor therapy\n* Patients with grade ≥2 neuropathy\n* Pregnant or breastfeeding women\n* Patients with a weight loss \\>10% within the previous 3 months\n* Patients with carcinomatous meningitis\n* Patients with a history of other malignant diseases within the past 3 years\n* Patients must have recovered from a major surgery at least 14 days prior to enrolment\n* Patients with active or uncontrolled infections or with serious medical conditions or disorders that may not allow patient management as established in the protocol\n* Prior treatment with antineoplasic drugs or thoracic radiotherapy for any reason different from the ones specific in the inclusion criteria\n* Patients who have received prior neo-adjuvant, adjuvant chemotherapy, radiotherapy, or chemo-radiotherapy with curative intent for non-metastatic disease less than 6 months before enrollment since the last chemotherapy, radiotherapy, or chemo-radiotherapy\n* Patients with a combination of small cell lung cancer and non-small cell lung cancer, a carcinoid lung tumor or large cell neuroendocrine carcinoma\n* Has known allergy or hypersensitivity to components of study drug\n* Significant comorbidities that preclude the administration of chemotherapy according to the investigator's criteria\n* Ongoing or recent evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments\n* Untreated brain metastasis(es) that may be considered active\n* Immunosuppressive corticosteroid doses within 4 weeks prior to the first dose of cemiplimab\n* Uncontrolled infection with hepatitis B or hepatitis C or human immunodeficiency virus; or diagnosis of immunodeficiency\n* History of interstitial lung disease or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management.\n* History of documented allergic reactions or acute hypersensitivity reactions attributed to antibody treatments\n* Patients with a history of solid organ transplant\n* Receipt of live vaccines within 30 days of first study treatment\n* Women of childbearing potential, or sexually active men, who are unwilling to practice highly effective contraception prior to the initial dose\u002Fstart of the first treatment prior to the start of the first treatment, during the study, and for at least 4 months after the last dose.",{"count":555,"type":21},63,[24],"This is an open-label, non-randomised, phase II, multicenter clinical trial. 63 stage IV or stage IIIB\u002FC not candidates for definitive chemo\u002Fradiotherapy or surgical resection non-small cell lung cancer (NSCLC) per the 8th edition TNM with no prior systemic anti-cancer therapy will be enrolled in this trial to determine whether therapy decision making based on ctDNA analysis improves overall survival.",[559,29,560,561,562,511],"Non Small Cell Lung Cancer Metastatic","Stage IV Non-small Cell Lung Cancer","Stage III Non-small Cell Lung Cancer","Respiratory Tract Neoplasms",[564,565,566,567],"Cemiplimab","ctDNA levels","Chemotherapy","Non-resectable non-small cell lung cancer","2025-11-17",{"date":570,"type":39},"2025-11-19",{"date":572,"type":39},"2025-07-29",{"date":574,"type":21},"2031-12-30",{"name":132,"class":46},{"id":577,"slug":578,"hasResults":12,"nctId":579,"briefTitle":580,"officialTitle":580,"acronym":581,"eligibilityCriteria":582,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":583,"targetDuration":4,"studyType":22,"phases":585,"briefSummary":586,"conditions":587,"keywords":589,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":568,"lastUpdatePostDateStruct":590,"startDateStruct":591,"completionDateStruct":593,"leadSponsor":595,"locationsCount":159},"100561043","phase-2-amikacin-liposome-inhalation-suspension-for-treatment-of-mycobacterium-xenopi-pulmonary-infection-100561043","NCT06585020","Amikacin Liposome Inhalation Suspension for Treatment of Mycobacterium Xenopi Pulmonary Infection","AKAPI","Inclusion Criteria:\n\n* 18 years old or older\n* with an highly effective or acceptable contraception\n* must present ATS\u002FIDSA 2020 criteria for nontuberculous mycobacterial pulmonary infection\n* the NTM should be M. xenopi\n\nExclusion Criteria:\n\n* Patients presenting any of the following criteria cannot be included:\n* Known hypersensitivity to one of the molecules of the study\n* Relapse of MX lung infection\n* Treatment with molecules able to interfere with cytochrome P450 that cannot be replaced by another therapeutic class\n* HIV 1 and 2 human immunodeficiency virus infection\n* Renal failure with creatinine clearance less than 30 mL\u002Fmin\n* Pregnancy and breastfeeding\n* Cystic fibrosis\n* Contraindications to one of the antibiotic :\n\nContraindication to the use of ARIKAYCE®:\n\n* Hypersensitivity to the active substance, to aminoglycosides or to any of the excipients listed in section 6.1 of the CPR.\n* Hypersensitivity to soy.\n* Co-administration with any other aminoglycoside, regardless of the route of administration\n* Severe Renal Failure\n\nContraindication to the use of Clarithromycine:\n\nAllergy to macrolides or to any of the excipients listed in section 6.1;\n\n* Association with :\n\n  * colchicine,\n  * ergot alkaloids, including for example dihydroergotamine, ergotamine, methylergometrine, methysergide: risk of ergotism,\n  * pimozide, mizolastine: risk of QT interval prolongation and cardiac rhythm disorders, in particular ventricular tachycardia, ventricular fibrillation and torsades de pointes,\n  * simvastatin, due to the increased risk of myopathy, including rhabdomyolysis.\n  * lomitapide,\n  * alfuzosin\n  * dapoxetine\n  * avanafil\n  * ivabradine,\n  * eplerenone,\n  * dronedarone,\n  * Quetiapine,\n  * ticagrelor,\n  * cisapride,\n  * astemizole,\n  * terfenadine,\n  * ranolazine,\n  * domperidone,\n* Congenital or acquired prolongation of the QT interval (see sections 4.4 and 4.5 of the CPR)\n* History of QT interval prolongation or ventricular rhythm disorders, in particular torsades de pointe (see sections 4.4 and 4.5 of the CPR);\n* Electrolyte imbalances (hypokalaemia or hypomagnesaemia, due to the risk of QT interval prolongation) (see sections 4.4 and 4.5 of the CPR).Clarithromycin should not be used in patients with severe hepatic insufficiency in association with renal insufficiency.\n\nContraindication to the use of Rifampicine:\n\n* Hypersensitivity to rifamycins or to any of the excipients listed in section 6.1 of the CPR.\n* Porphyrias.\n* Association with bictegravir, cobicistat, daclatasvir, dasabuvir, delamanid, grazoprevir\u002Felbasvir, ritonavir-boosted protease inhibitors, isavuconazole, lédipasvir, lurasidone, midostaurine, ombitasvir\u002Fparitaprévir, praziquantel, rilpivirine, sofosbuvir, velpatasvir, voriconazole, voxilaprévir, (see section 4. 5 of the CPR). In children under 6 years of age, due to the risk of malaria\n\nContradiction the the use of Ethambutol:\n\n* Known hypersensitivity to ethambutol\n* Optic neuritis\n* This medicine is contraindicated in patients with a wheat allergy (other than coeliac disease).\n* Inability to comply with the requirements of the protocol, especially substance abuse, according to the investigator.\n* Limited life expectancy (e.g 3 months)\n* Patients with hematologic malignancies and allogeneic haematopoietic stem cells\n* Women of childbearing age and not using an effective method of contraception (Pearl Index \\\u003C1%)\n* The patient is treated with molecules prolonging the QT interval that cannot be replaced by another therapeutic class.\n* The patient presents a heart failure with left ventricular ejection fraction less than 30%.",{"count":584,"type":21},190,[24],"Treatment of Mycobacterium xenopi (MX) lung disease is not-well- tolerated and concerned a growing number of patients, especially with chronic pulmonary diseases or immunosuppression. The outcome of these patients is poor, and treatment is very long. Indeed, this duration is based on the date of sputum conversion. Treatment should be continued until 12 months after sputum conversion. In the vast majority patients have converted after 6 months of treatment, so a 18 months duration in total. Unfortunately, few data are available for MX, as it is rare in USA, but it is the second NTM isolated in France and concerns an increasing number of patients. As it is uncommon in USA, no clinical studies conducted by the pharmaceutical laboratory will be planned. In a murine model of MX infection, the only drug which decreased the number colony formant units in mice lungs, was amikacin. Until now, amikacin was only available intravenously and used only for patients with very severe disease, because of renal and auditory toxicity. Amikacin liposome inhalation suspension (ARIKAYCE®) is amikacin sulfate encapsulated in liposomes for inhalational delivery. ARIKAYCE® increases amikacin uptake into alveolar macrophages, a refuge for NTM organisms; allows biofilm penetration; and limits systemic amikacin exposure ARIKAYCE® has already be tested in a randomized study on M. avium complex (MAC) refractory pulmonary infections. In this study, the culture conversion rate in the ARIKAYCE® group was higher than standard regimen group.",[588,29],"Mycobacterium; Xenopi",[588,29],{"date":570,"type":39},{"date":592,"type":39},"2024-10-20",{"date":594,"type":21},"2027-08",{"name":596,"class":46},"Centre Hospitalier Universitaire, Amiens",{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":4,"eligibilityCriteria":603,"healthyVolunteers":12,"sex":17,"minAge":604,"maxAge":605,"enrollmentInfo":606,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":608,"conditions":609,"keywords":611,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":613,"lastUpdatePostDateStruct":614,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":159},"100602677","validation-of-the-spot-mas-lung-test-using-circulating-tumor-dna-for-the-detection-of-lung-cancer-100602677","NCT07126626","Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer","Multi-center Prospective Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer","Inclusion Criteria:\n\nCohort A\n\n1. Volunteers (participants) aged 50-80 years at the time of consent.\n\n   1. 50% smokers with a smoking history of 20 pack-years who currently smoke or have quit within the past 15 years.\n   2. 50% never-smokers or light smokers (\\\u003C 20 pack-years or quit \\> 15 years) who are first- or second-degree relatives of LC patients.\n2. Willing to undergo LDCT\u002FNCCT of the chest for lung cancer screening.\n3. Willing to consent to an investigational blood draw during the index LDCT\u002FNCCT screening visit and before any invasive procedures or treatment for lung cancer diagnosis.\n4. Willing to consent to a 1-year follow-up and additional follow-ups as per protocol.\n\nCohort B\n\n1. Subjects aged 50-80 years at the time of consent.\n\n   1. 50% smokers with a smoking history of 20 pack-years who currently smoke or have quit within the past 15 years.\n   2. 50% never-smokers or light smokers (\\\u003C 20 pack-years or quit \\> 15 years) who are first- or second-degree relatives of LC patients.\n2. Have undergone LDCT\u002FNCCT of the chest for lung cancer screening\u002Fdiagnosis, including only high-risk lesions (LUNG-RADS 4).\n3. Willing to consent to an investigational blood draw before any invasive procedures (CECT\u002FPET-CT\u002Fbiopsy) or treatment for lung cancer diagnosis.\n4. Willing to consent to a 1-year follow-up and additional follow-ups as per protocol.\n\nExclusion Criteria for both Cohort A and Cohort B\n\n1. Subject has a health problem that substantially limits life expectancy and\u002For the ability or willingness to have curative lung surgery.\n2. Subject is undergoing CECT for investigation of highly suspicious symptoms for lung cancer.\n3. Pre-existing or history of lung cancer.\n4. History of any malignancy (subjects who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study).\n5. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs.\n6. Currently receiving treatment for pneumonia.\n7. Any major physical trauma (e.g., disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent.\n8. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study.\n9. Participation in a clinical research study in which an experimental medication and\u002For medical procedure has been administered or may be administered within the 30 days leading up to providing informed consent or may be administered through the time of subject screening.\n\n   \\-\n\n   Exclusion Criteria:\n\n   \\-","50 Years","80 Years",{"count":607,"type":21},1184,"This is an observational clinical trial, aiming to evaluate the efficacy of the SPOTMAS LUNG (SML) test compared to Low dose CTScan (LDCT)\u002FNone contrast CTScan (NCCT) in two distinct risk populations:\n\n* Cohort A: To demonstrate that SML is concordant with LDCT\u002FNCCT in general population lung cancer screening, including low-risk (LRs0-1-2), intermediate-risk (LRs3), and high-risk (LRs4) groups.\n* Cohort B: To validate the sensitivity and specificity of SML in the high-risk group (LRs4).",[29,610],"Lung Cancer Screening",[612],"SPOT-MAS Lung Test","2025-08-10",{"date":615,"type":39},"2025-08-17",{"date":617,"type":21},"2025-08-18",{"date":619,"type":21},"2027-07-31",{"name":621,"class":72},"Gene Solutions",{"id":623,"slug":624,"hasResults":12,"nctId":625,"briefTitle":626,"officialTitle":626,"acronym":4,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":628,"maxAge":629,"enrollmentInfo":630,"targetDuration":4,"studyType":22,"phases":632,"briefSummary":633,"conditions":634,"keywords":637,"overallStatus":182,"whyStopped":4,"lastUpdateSubmitDate":641,"lastUpdatePostDateStruct":642,"startDateStruct":644,"completionDateStruct":646,"leadSponsor":648,"locationsCount":73},"100597624","pivotal-study-to-assess-safety-and-performance-of-neola-a-novel-lung-monitoring-device-for-neonates-100597624","NCT07060911","Pivotal Study to Assess Safety and Performance of Neola®, a Novel Lung Monitoring Device for Neonates","IInclusion criteria:\n\n* Preterm or term born neonates with gestational age between 26 and 40 weeks\n* Age between 1 day post-natal and 44 weeks corrected gestational age\n* Weight between 1000 g and 3500 g\n* Patient treated at a neonatal intensive care unit.\n* Patient is either on invasive mechanical ventilation, on CPAP or NIPPV or receives respiratory support via high-flow nasal cannula (≥2L\u002Fmin)\n* Signed informed consent prior to any study related procedures by the legal representatives of the patient\n\nExclusion criteria:\n\n* Known cardiopulmonary congenital anomalies\n* Patients with trisomies or other chromosomal abnormality\n* Patients not expected to survive\n* Non-intact skin or other skin conditions (such as skin lesions) that do not allow the use of skin adhesives. (e.g., Bullous impetigo, Staphylococcal scalded skin syndrome, localized lesions of herpes simplex virus)\n* Thorax curvature does not allow placement of the probe sets without air between the surface of the probes and the skin.","1 Day","44 Weeks",{"count":631,"type":21},22,[172],"Pivotal study to assess safety and performance of Neola®, a novel lung monitoring device for neonates",[635,636,29],"RDS of Prematurity","Preterm Birth",[638,639,640],"GASMAS","Spectroscopy","Gas absorption spectroscopy","2025-07-02",{"date":643,"type":39},"2025-07-11",{"date":645,"type":21},"2026-03",{"date":647,"type":21},"2027-02",{"name":649,"class":72},"Neola Medical Inc",{"id":651,"slug":652,"hasResults":12,"nctId":653,"briefTitle":654,"officialTitle":655,"acronym":656,"eligibilityCriteria":657,"healthyVolunteers":168,"sex":17,"minAge":18,"maxAge":658,"enrollmentInfo":659,"targetDuration":4,"studyType":22,"phases":661,"briefSummary":662,"conditions":663,"keywords":665,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":674,"locationsCount":159},"100587206","housing-environment-and-living-conditions-for-transformed-health-100587206","NCT06925373","Housing, Environment, And Living Conditions for Transformed Health","Housing, Environment, And Living Conditions for Transformed Health (HEALTHe Birmingham)","HEALTHe","Inclusion Criteria:\n\n* Adults age 18 years and older\n* English speaking\n* Residents of one of 4 public housing site in Birmingham, Alabama\n\nExclusion Criteria:\n\n* Individuals who are not 18 years or older\n* Do not speak English\n* Do not meet the residency criteria","89 Years",{"count":660,"type":21},460,[172],"This project will compare the health effects of public housing renovation, neighborhood built and social environment improvements, and indoor air purification, alone and in combination, as well as the cost effectiveness of each approach.\n\nSTUDY 1: The study will assess the effects of public housing and neighborhood environment (built and social) improvements on health-related behaviors, psychosocial and physiologic stress, and self-reported and physiological markers of lung health and chronic disease.\n\nSTUDY 2: The study will determine whether indoor air purification can positively impact lung health in public housing sites not undergoing housing renovation, comparing a site near industrial pollution vs one less contaminated.",[29,664],"Chronic Disease",[666,664],"Lung Health","2025-06-19",{"date":669,"type":39},"2025-06-25",{"date":671,"type":39},"2025-06-18",{"date":673,"type":21},"2028-07",{"name":675,"class":46},"University of Alabama at Birmingham"]